{"disease":{"id":"small-cell-lung-carcinoma-extensive-disease","name":"small cell lung carcinoma extensive disease"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03043872","title":"Durvalumab ± Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (CASPIAN)","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":987,"lead_sponsor_name":"AstraZeneca","has_results":true},{"nct_id":"NCT04449861","title":"Durvalumab Plus Chemotherapy in ES-SCLC (Oriental)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":166,"lead_sponsor_name":"AstraZeneca","has_results":true},{"nct_id":"NCT04712903","title":"Durvalumab Plus Chemotherapy in Untreated Patients With Extensive-Stage Small Cell Lung Cancer","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":101,"lead_sponsor_name":"AstraZeneca","has_results":true}],"total":3},"guidelines":[],"source":"Drug Landscape verified database"}